OTCMKTS:SNNAQ

Sienna Biopharmaceuticals Competitors

$0.03

-0.01 (-20.63 %)

(As of 04/20/2021 05:19 PM ET)

Add

Compare

Today's Range

$0.02

Now: $0.03▼

$0.03

50-Day Range

$0.02

MA: $0.03▼

$0.04

52-Week Range

$0.00

Now: $0.03▼

$0.07

Volume40,855 shs

Average Volume131,458 shs

Market Capitalization$581,456.80

P/E RatioN/A

Dividend YieldN/A

Beta1.73

Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) Vs. VVUSQ, IMUCD, NSPX, ETST, BTHE, and IMUC

Should you be buying SNNAQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Sienna Biopharmaceuticals, including VIVUS (VVUSQ), ImmunoCellular Therapeutics (IMUCD), Inspyr Therapeutics (NSPX), Earth Science Tech (ETST), Boston Therapeutics (BTHE), and ImmunoCellular Therapeutics (IMUC).

Sienna Biopharmaceuticals vs. VIVUS Stock

Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) and VIVUS (OTCMKTS:VVUSQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Sienna Biopharmaceuticals and VIVUS, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sienna Biopharmaceuticals	0	0	0	0	N/A
VIVUS	0	0	0	0	N/A

Risk and Volatility

Sienna Biopharmaceuticals has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500. Comparatively, VIVUS has a beta of -3.25, meaning that its share price is 425% less volatile than the S&P 500.

Earnings and Valuation

This table compares Sienna Biopharmaceuticals and VIVUS's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sienna Biopharmaceuticals	N/A	N/A	$-73,470,000.00	N/A	N/A
VIVUS	$69.76 million	0.03	$-31,500,000.00	($2.96)	-0.04

VIVUS has higher revenue and earnings than Sienna Biopharmaceuticals.

Profitability

This table compares Sienna Biopharmaceuticals and VIVUS's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sienna Biopharmaceuticals	N/A	N/A	N/A
VIVUS	-39.28%	N/A	-12.18%

Institutional and Insider Ownership

7.3% of VIVUS shares are owned by institutional investors. 27.2% of Sienna Biopharmaceuticals shares are owned by company insiders. Comparatively, 12.0% of VIVUS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Sienna Biopharmaceuticals beats VIVUS on 4 of the 7 factors compared between the two stocks.

Sienna Biopharmaceuticals vs. ImmunoCellular Therapeutics Stock

Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Sienna Biopharmaceuticals and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sienna Biopharmaceuticals	N/A	N/A	N/A
ImmunoCellular Therapeutics	N/A	N/A	N/A

Valuation and Earnings

This table compares Sienna Biopharmaceuticals and ImmunoCellular Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sienna Biopharmaceuticals	N/A	N/A	$-73,470,000.00	N/A	N/A
ImmunoCellular Therapeutics	N/A	N/A	$-14,310,000.00	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Sienna Biopharmaceuticals and ImmunoCellular Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sienna Biopharmaceuticals	0	0	0	0	N/A
ImmunoCellular Therapeutics	0	0	0	0	N/A

Volatility & Risk

Sienna Biopharmaceuticals has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.

Sienna Biopharmaceuticals vs. Inspyr Therapeutics Stock

Inspyr Therapeutics (OTCMKTS:NSPX) and Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for Inspyr Therapeutics and Sienna Biopharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspyr Therapeutics	0	0	0	0	N/A
Sienna Biopharmaceuticals	0	0	0	0	N/A

Profitability

This table compares Inspyr Therapeutics and Sienna Biopharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inspyr Therapeutics	N/A	N/A	-298.11%
Sienna Biopharmaceuticals	N/A	N/A	N/A

Risk & Volatility

Inspyr Therapeutics has a beta of -16.55, suggesting that its share price is 1,755% less volatile than the S&P 500. Comparatively, Sienna Biopharmaceuticals has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500.

Earnings and Valuation

This table compares Inspyr Therapeutics and Sienna Biopharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspyr Therapeutics	N/A	N/A	$-930,000.00	N/A	N/A
Sienna Biopharmaceuticals	N/A	N/A	$-73,470,000.00	N/A	N/A

Summary

Sienna Biopharmaceuticals beats Inspyr Therapeutics on 2 of the 3 factors compared between the two stocks.

Sienna Biopharmaceuticals vs. Earth Science Tech Stock

Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) and Earth Science Tech (OTCMKTS:ETST) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Volatility and Risk

Sienna Biopharmaceuticals has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500. Comparatively, Earth Science Tech has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Sienna Biopharmaceuticals and Earth Science Tech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sienna Biopharmaceuticals	0	0	0	0	N/A
Earth Science Tech	0	0	0	0	N/A

Earnings & Valuation

This table compares Sienna Biopharmaceuticals and Earth Science Tech's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sienna Biopharmaceuticals	N/A	N/A	$-73,470,000.00	N/A	N/A
Earth Science Tech	$530,000.00	3.39	$-1,200,000.00	N/A	N/A

Earth Science Tech has higher revenue and earnings than Sienna Biopharmaceuticals.

Profitability

This table compares Sienna Biopharmaceuticals and Earth Science Tech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sienna Biopharmaceuticals	N/A	N/A	N/A
Earth Science Tech	-1,750.31%	N/A	-2,929.76%

Summary

Earth Science Tech beats Sienna Biopharmaceuticals on 3 of the 5 factors compared between the two stocks.

Sienna Biopharmaceuticals vs. Boston Therapeutics Stock

Boston Therapeutics (OTCMKTS:BTHE) and Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Volatility and Risk

Boston Therapeutics has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500. Comparatively, Sienna Biopharmaceuticals has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Boston Therapeutics and Sienna Biopharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Therapeutics	0	0	0	0	N/A
Sienna Biopharmaceuticals	0	0	0	0	N/A

Profitability

This table compares Boston Therapeutics and Sienna Biopharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Boston Therapeutics	-24,627.27%	N/A	-3,480.61%
Sienna Biopharmaceuticals	N/A	N/A	N/A

Earnings and Valuation

This table compares Boston Therapeutics and Sienna Biopharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boston Therapeutics	$20,000.00	87.24	$-3,690,000.00	N/A	N/A
Sienna Biopharmaceuticals	N/A	N/A	$-73,470,000.00	N/A	N/A

Boston Therapeutics has higher revenue and earnings than Sienna Biopharmaceuticals.

Summary

Sienna Biopharmaceuticals beats Boston Therapeutics on 3 of the 5 factors compared between the two stocks.

Sienna Biopharmaceuticals vs. ImmunoCellular Therapeutics Stock

ImmunoCellular Therapeutics (OTCMKTS:IMUC) and Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Profitability

This table compares ImmunoCellular Therapeutics and Sienna Biopharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmunoCellular Therapeutics	N/A	N/A	N/A
Sienna Biopharmaceuticals	N/A	N/A	N/A

Valuation and Earnings

This table compares ImmunoCellular Therapeutics and Sienna Biopharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunoCellular Therapeutics	N/A	N/A	N/A	N/A	N/A
Sienna Biopharmaceuticals	N/A	N/A	$-73,470,000.00	N/A	N/A

Analyst Ratings

This is a summary of current ratings and target prices for ImmunoCellular Therapeutics and Sienna Biopharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunoCellular Therapeutics	0	0	0	0	N/A
Sienna Biopharmaceuticals	0	0	0	0	N/A

Risk and Volatility

ImmunoCellular Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Sienna Biopharmaceuticals has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.

Summary

Sienna Biopharmaceuticals beats ImmunoCellular Therapeutics on 1 of the 1 factors compared between the two stocks.